Pacira BioSciences Inc.

NASDAQ: PCRX · Real-Time Price · USD
26.78
-0.12 (-0.45%)
At close: May 01, 2025, 3:59 PM
25.63
-4.29%
After-hours: May 01, 2025, 06:39 PM EDT

Company Description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States.

The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure.

The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.

Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences Inc.
Pacira BioSciences Inc. logo
Country United States
IPO Date Feb 3, 2011
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 788
CEO Frank D. Lee

Contact Details

Address:
5401 West Kennedy Boulevard
Tampa, Florida
United States
Website https://www.pacira.com

Stock Details

Ticker Symbol PCRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001396814
CUSIP Number 695127100
ISIN Number US6951271005
Employer ID 51-0619477
SIC Code 2834

Key Executives

Name Position
Frank D. Lee Chief Executive Officer & Director
Shawn M. Cross Chief Financial Officer
Charles A. Reinhart III, CPA, M.B.A. Executive Officer
Christopher C. Young Chief Manufacturing Officer
David M. Stack Advisor
Dr. Jonathan Slonin M.D. Chief Medical Officer
Kristen Williams Esq., J.D. Chief Administrative Officer & Secretary
Krys Corbett Esq. Chief Business Officer
Lauren Bullaro Riker Principal Accounting Officer & Senior Vice President of Finance
Susan Mesco Head of Investor Relations

Latest SEC Filings

Date Type Title
Apr 29, 2025 ARS Filing
Apr 29, 2025 DEFA14A Filing
Apr 29, 2025 DEF 14A Filing
Apr 28, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 22, 2025 8-K Current Report
Apr 21, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 18, 2025 DEFA14A Filing
Apr 17, 2025 DEFA14A Filing
Apr 07, 2025 8-K Current Report
Mar 14, 2025 8-K Current Report